Kalii Chloridum/Glucosum B. Braun (Glucose, Anhydrous, Potassium Chloride)

The potassium chloride component releases potassium ions that raise extracellular potassium concentrations, correcting hypokalemia. Glucose anhydrous provides an immediate energy source, stimulates insulin release, and contributes to osmotic balance, helping maintain fluid distribution and cellular metabolism during IV therapy.

The dose is individualized and set by the prescribing clinician based on the patient’s serum potassium, glucose levels, renal function, and overall clinical condition. The healthcare professional determines the infusion rate, concentration, and duration of therapy.

Safety data for use during pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike standalone potassium chloride injections, this formulation combines potassium with glucose, offering both electrolyte correction and an energy source in a single bag. Compared with separate dextrose solutions, it reduces the need for multiple infusions and simplifies fluid management, though clinicians must still monitor both potassium and glucose levels closely.

The product must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Before use, inspect for particulate matter and ensure the solution is at room temperature if required for administration.

It is administered intravenously, typically by slow infusion through a peripheral or central line. The solution may be diluted with compatible IV fluids according to the prescriber’s instructions, and infusion rates are adjusted based on the patient’s electrolyte and glucose monitoring results.

The most serious risks include severe hyperkalemia leading to cardiac arrhythmias, anaphylactic reactions, severe hyperglycemia with possible ketoacidosis, and significant electrolyte imbalances that can cause muscle weakness or cardiac complications. Immediate medical attention is required if any of these occur.

Patients with known hyperkalemia, severe renal failure, or a documented hypersensitivity to potassium chloride, glucose, or any excipients in the formulation should not receive this injection. Contraindications must be confirmed by the prescribing clinician before therapy.